vs

Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Empire State Realty OP, L.P. (ESBA). Click either name above to swap in a different company.

ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $199.2M, roughly 1.4× Empire State Realty OP, L.P.). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 16.1%, a 80.2% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 0.8%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 4.9%).

Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.

Empire State Realty OP, L.P. is a real estate operating partnership focused on owning, managing, and leasing premium commercial and retail properties primarily in the New York City metropolitan area. Its portfolio includes iconic landmarks like the Empire State Building, serving corporate tenants, retail brands and tourism-related business segments.

ACAD vs ESBA — Head-to-Head

Bigger by revenue
ACAD
ACAD
1.4× larger
ACAD
$284.0M
$199.2M
ESBA
Growing faster (revenue YoY)
ACAD
ACAD
+8.6% gap
ACAD
9.4%
0.8%
ESBA
Higher net margin
ACAD
ACAD
80.2% more per $
ACAD
96.3%
16.1%
ESBA
Faster 2-yr revenue CAGR
ACAD
ACAD
Annualised
ACAD
17.5%
4.9%
ESBA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACAD
ACAD
ESBA
ESBA
Revenue
$284.0M
$199.2M
Net Profit
$273.6M
$32.2M
Gross Margin
90.8%
Operating Margin
6.1%
17.8%
Net Margin
96.3%
16.1%
Revenue YoY
9.4%
0.8%
Net Profit YoY
90.3%
71.2%
EPS (diluted)
$1.61
$0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACAD
ACAD
ESBA
ESBA
Q4 25
$284.0M
$199.2M
Q3 25
$278.6M
$197.7M
Q2 25
$264.6M
$191.3M
Q1 25
$244.3M
$180.1M
Q4 24
$259.6M
$197.6M
Q3 24
$250.4M
$199.6M
Q2 24
$242.0M
$189.5M
Q1 24
$205.8M
$181.2M
Net Profit
ACAD
ACAD
ESBA
ESBA
Q4 25
$273.6M
$32.2M
Q3 25
$71.8M
$13.6M
Q2 25
$26.7M
$11.4M
Q1 25
$19.0M
$15.8M
Q4 24
$143.7M
$18.8M
Q3 24
$32.8M
$22.8M
Q2 24
$33.4M
$28.6M
Q1 24
$16.6M
$10.2M
Gross Margin
ACAD
ACAD
ESBA
ESBA
Q4 25
90.8%
Q3 25
92.2%
Q2 25
92.2%
Q1 25
91.7%
Q4 24
91.6%
Q3 24
92.5%
Q2 24
92.5%
Q1 24
88.8%
Operating Margin
ACAD
ACAD
ESBA
ESBA
Q4 25
6.1%
17.8%
Q3 25
12.8%
19.9%
Q2 25
12.2%
18.4%
Q1 25
7.9%
14.3%
Q4 24
59.1%
21.7%
Q3 24
12.6%
22.7%
Q2 24
12.6%
20.8%
Q1 24
7.4%
17.1%
Net Margin
ACAD
ACAD
ESBA
ESBA
Q4 25
96.3%
16.1%
Q3 25
25.8%
6.9%
Q2 25
10.1%
6.0%
Q1 25
7.8%
8.8%
Q4 24
55.4%
9.5%
Q3 24
13.1%
11.4%
Q2 24
13.8%
15.1%
Q1 24
8.0%
5.6%
EPS (diluted)
ACAD
ACAD
ESBA
ESBA
Q4 25
$1.61
$0.11
Q3 25
$0.42
$0.05
Q2 25
$0.16
$0.04
Q1 25
$0.11
$0.05
Q4 24
$0.86
$0.07
Q3 24
$0.20
$0.08
Q2 24
$0.20
$0.10
Q1 24
$0.10
$0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACAD
ACAD
ESBA
ESBA
Cash + ST InvestmentsLiquidity on hand
$177.7M
$132.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.2B
Total Assets
$1.6B
$4.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACAD
ACAD
ESBA
ESBA
Q4 25
$177.7M
$132.7M
Q3 25
$258.0M
$154.1M
Q2 25
$253.6M
$94.6M
Q1 25
$217.7M
$187.8M
Q4 24
$319.6M
$385.5M
Q3 24
$155.1M
$421.9M
Q2 24
$177.1M
$535.5M
Q1 24
$204.7M
$333.6M
Stockholders' Equity
ACAD
ACAD
ESBA
ESBA
Q4 25
$1.2B
Q3 25
$917.3M
Q2 25
$822.4M
Q1 25
$765.2M
Q4 24
$732.8M
Q3 24
$577.2M
Q2 24
$516.7M
Q1 24
$464.0M
Total Assets
ACAD
ACAD
ESBA
ESBA
Q4 25
$1.6B
$4.5B
Q3 25
$1.3B
$4.1B
Q2 25
$1.2B
$4.1B
Q1 25
$1.1B
$4.1B
Q4 24
$1.2B
$4.5B
Q3 24
$976.9M
$4.4B
Q2 24
$914.1M
$4.4B
Q1 24
$855.1M
$4.2B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACAD
ACAD
ESBA
ESBA
Operating Cash FlowLast quarter
$-48.7M
$249.1M
Free Cash FlowOCF − Capex
$50.6M
FCF MarginFCF / Revenue
25.4%
Capex IntensityCapex / Revenue
99.6%
Cash ConversionOCF / Net Profit
-0.18×
7.74×
TTM Free Cash FlowTrailing 4 quarters
$109.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACAD
ACAD
ESBA
ESBA
Q4 25
$-48.7M
$249.1M
Q3 25
$74.3M
$105.3M
Q2 25
$64.0M
$26.7M
Q1 25
$20.3M
$83.1M
Q4 24
$40.4M
$260.9M
Q3 24
$63.2M
$102.8M
Q2 24
$25.0M
$37.1M
Q1 24
$29.1M
$70.9M
Free Cash Flow
ACAD
ACAD
ESBA
ESBA
Q4 25
$50.6M
Q3 25
$73.9M
$72.8M
Q2 25
$-55.1M
Q1 25
$41.1M
Q4 24
$88.0M
Q3 24
$63.2M
$-65.1M
Q2 24
$19.5M
Q1 24
$23.2M
FCF Margin
ACAD
ACAD
ESBA
ESBA
Q4 25
25.4%
Q3 25
26.5%
36.8%
Q2 25
-28.8%
Q1 25
22.8%
Q4 24
44.5%
Q3 24
25.2%
-32.6%
Q2 24
10.3%
Q1 24
12.8%
Capex Intensity
ACAD
ACAD
ESBA
ESBA
Q4 25
99.6%
Q3 25
0.1%
16.5%
Q2 25
42.8%
Q1 25
23.4%
Q4 24
87.5%
Q3 24
0.0%
84.1%
Q2 24
9.3%
Q1 24
26.3%
Cash Conversion
ACAD
ACAD
ESBA
ESBA
Q4 25
-0.18×
7.74×
Q3 25
1.03×
7.72×
Q2 25
2.40×
2.35×
Q1 25
1.07×
5.27×
Q4 24
0.28×
13.88×
Q3 24
1.93×
4.51×
Q2 24
0.75×
1.30×
Q1 24
1.76×
6.94×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACAD
ACAD

Nuplazid$174.4M61%
Daybue$109.6M39%

ESBA
ESBA

Real Estate Segment$163.8M82%
Observatory Segment$35.2M18%

Related Comparisons